miRNA-Coordinated Networks as Promising Therapeutic Targets for Acute Kidney Injury

American Journal of Pathology

Volumn 187, Issue 1, 2017, Pages 20-24

  van Zonneveld, Anton Jan ^a   Rabelink, Ton J ^a   Bijkerk, Roel ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MICRORNA 182; STROMAL CELL DERIVED FACTOR 1;

ACUTE KIDNEY FAILURE; ANTISENSE THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; HUMAN; KIDNEY ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; ACUTE KIDNEY INJURY; ANIMAL; CELL CYCLE; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; CELL CYCLE; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 85006380591     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2016.10.017     Document Type: Article

References (30)

1. 1 Wilflingseder, J., Jelencsis, K., Bergmeister, H., Sunzenauer, J., Regele, H., Eskandary, F., Reindl-Schwaighofer, R., Kainz, A., Oberbauer, R., miR-182-5p inhibition ameliorates ischmic acute kidney injury. Am J Pathol 187 (2017), 70–79.
2. 2 Zuk, A., Bonventre, J.V., Acute kidney injury. Annu Rev Med 67 (2016), 293–307.
3. 3 Mehta, R.L., Cerda, J., Burdmann, E.A., Tonelli, M., Garcia-Garcia, G., Jha, V., Susantitaphong, P., Rocco, M., Vanholder, R., Sever, M.S., Cruz, D., Jaber, B., Lameire, N.H., Lombardi, R., Lewington, A., Feehally, J., Finkelstein, F., Levin, N., Pannu, N., Thomas, B., Aronoff-Spencer, E., Remuzzi, G., International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385 (2015), 2616–2643.
4. 4 Torio CM, Andrews RM: National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality, 2013. Available at https://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp (accessed October 10, 2016).
5. 5 Bonventre, J.V., Yang, L., Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121 (2011), 4210–4221.
6. 6 Heinze, G., Collins, S., Benedict, M.A., Nguyen, L.L., Kramar, R., Winkelmayer, W.C., Haas, M., Kainz, A., Oberbauer, R., The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 82 (2006), 1441–1448.
7. 7 Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
8. 8 van Solingen, C., Bijkerk, R., de Boer, H.C., Rabelink, T.J., van Zonneveld, A.J., The role of microRNA-126 in vascular homeostasis. Curr Vasc Pharmacol 13 (2015), 341–351.
9. 9 Cantaluppi, V., Gatti, S., Medica, D., Figliolini, F., Bruno, S., Deregibus, M.C., Sordi, A., Biancone, L., Tetta, C., Camussi, G., Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82 (2012), 412–427.
10. 10 Bijkerk, R., van Solingen, C., de Boer, H.C., van der Pol, P., Khairoun, M., de Bruin, R.G., van Oeveren-Rietdijk, A.M., Lievers, E., Schlagwein, N., van Gijlswijk, D.J., Roeten, M.K., Neshati, Z., de Vries, A.A., Rodijk, M., Pike-Overzet, K., van den Berg, Y.W., van der Veer, E.P., Versteeg, H.H., Reinders, M.E., Staal, F.J., van Kooten, C., Rabelink, T.J., van Zonneveld, A.J., Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity. J Am Soc Nephrol 25 (2014), 1710–1722.
11. 11 Meng, S., Cao, J.T., Zhang, B., Zhou, Q., Shen, C.X., Wang, C.Q., Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 53 (2012), 64–72.
12. 12 Wilflingseder, J., Sunzenauer, J., Toronyi, E., Heinzel, A., Kainz, A., Mayer, B., Perco, P., Telkes, G., Langer, R.M., Oberbauer, R., Molecular pathogenesis of post transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles. PloS One, 9, 2014, e104164.
13. 13 Garcia, M.A., Meca, R., Leite, D., Boim, M.A., Effect of renal ischemia/reperfusion on gene expression of a pH-sensitive K+ channel. Nephron Physiol 106 (2007), 1–7.
14. 14 Liu, J., Qin, J., Mei, W., Zhang, H., Yuan, Q., Peng, Z., Luo, R., Yuan, X., Huang, L., Tao, L., Expression of niban in renal interstitial fibrosis. Nephrology (Carlton) 19 (2014), 479–489.
15. 15 Yang, L., Besschetnova, T.Y., Brooks, C.R., Shah, J.V., Bonventre, J.V., Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16 (2010), 535–543 531p following 143.
16. 16 Lovisa, S., LeBleu, V.S., Tampe, B., Sugimoto, H., Vadnagara, K., Carstens, J.L., Wu, C.C., Hagos, Y., Burckhardt, B.C., Pentcheva-Hoang, T., Nischal, H., Allison, J.P., Zeisberg, M., Kalluri, R., Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 21 (2015), 998–1009.
17. 17 Grande, M.T., Sanchez-Laorden, B., Lopez-Blau, C., De Frutos, C.A., Boutet, A., Arevalo, M., Rowe, R.G., Weiss, S.J., Lopez-Novoa, J.M., Nieto, M.A., Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med 21 (2015), 989–997.
18. 18 Krishnan, K., Steptoe, A.L., Martin, H.C., Wani, S., Nones, K., Waddell, N., Mariasegaram, M., Simpson, P.T., Lakhani, S.R., Gabrielli, B., Vlassov, A., Cloonan, N., Grimmond, S.M., MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA 19 (2013), 230–242.
19. 19 Kouri, F.M., Hurley, L.A., Daniel, W.L., Day, E.S., Hua, Y., Hao, L., Peng, C.Y., Merkel, T.J., Queisser, M.A., Ritner, C., Zhang, H., James, C.D., Sznajder, J.I., Chin, L., Giljohann, D.A., Kessler, J.A., Peter, M.E., Mirkin, C.A., Stegh, A.H., miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev 29 (2015), 732–745.
20. 20 Taylor, W.R., Stark, G.R., Regulation of the G2/M transition by p53. Oncogene 20 (2001), 1803–1815.
21. 21 Bijkerk, R., de Bruin, R.G., van Solingen, C., van Gils, J.M., Duijs, J.M., van der Veer, E.P., Rabelink, T.J., Humphreys, B.D., van Zonneveld, A.J., Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation. Kidney Int 89 (2016), 1268–1280.
22. 22 Fan, P.C., Chen, C.C., Chen, Y.C., Chang, Y.S., Chu, P.H., MicroRNAs in acute kidney injury. Hum Genomics, 10, 2016, 29.
23. 23 Li, Z., Rana, T.M., Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13 (2014), 622–638.
24. 24 Ebert, M.S., Neilson, J.R., Sharp, P.A., MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4 (2007), 721–726.
25. 25 Gumireddy, K., Young, D.D., Xiong, X., Hogenesch, J.B., Huang, Q., Deiters, A., Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 47 (2008), 7482–7484.
26. 26 Matsui, M., Corey, D.R., Non-coding RNAs as drug targets. Nat Rev Drug Discov, 2016 [Epub ahead of print] doi:10.1038/nrd.2016.117.
27. 27 Bouchie, A., First microRNA mimic enters clinic. Nat Biotechnol, 31, 2013, 577.
28. 28 Agostini, M., Knight, R.A., miR-34: from bench to bedside. Oncotarget 5 (2014), 872–881.
29. 29 Gomez, I.G., MacKenna, D.A., Johnson, B.G., Kaimal, V., Roach, A.M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., Xia, T.H., Liu, X., Borza, D.B., Grafals, M., Shankland, S.J., Himmelfarb, J., Portilla, D., Liu, S., Chau, B.N., Duffield, J.S., Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125 (2015), 141–156.
30. 30 Lindow, M., Kauppinen, S., Discovering the first microRNA-targeted drug. J Cell Biol 199 (2012), 407–412.